Bladder Cancer’s Immune Landscape Comes Into Focus

Study on immunohistochemical classification of MIBC.

Evaluated 124 urothelial carcinoma patients.

Tumors classified as luminal, basal, other.

PD-1 expressed in 70.5 percent of tumors.

Higher PD-1 in luminal tumors (84.2 percent).

PD-L1 observed in 40 percent of tumors, higher in basal.

Study did not assess survival outcomes.

Findings may guide therapeutic strategies.